Lilly's retatrutide delivers more than double Ozempic's weight loss in Phase 3 trial

PUBT · 2d ago
Lilly's retatrutide delivers more than double Ozempic's weight loss in Phase 3 trial
  • Eli Lilly announced positive Phase 3 results for retatrutide versus Ozempic in adults with type 2 diabetes.
  • Retatrutide delivered greater blood sugar reductions and substantially more weight loss than Ozempic’s highest approved dose, meeting all key trial endpoints.
  • Gastrointestinal problems were the most common adverse events; treatment discontinuations due to adverse events were higher with retatrutide.
  • The investigational drug has not received regulatory approval anywhere; detailed results will be presented at a future medical meeting and published.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Eli Lilly and Company published the original content used to generate this news brief via PR Newswire (Ref. ID: 202610280645PR_NEWS_USPR_____DE82302) on October 28, 2026, and is solely responsible for the information contained therein.